GSK2292767
Modify Date: 2024-01-02 17:54:35
GSK2292767 structure
|
Common Name | GSK2292767 | ||
|---|---|---|---|---|
| CAS Number | 1254036-66-2 | Molecular Weight | 512.58100 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H28N6O5S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of GSK2292767GSK2292767 is a potent and selective inhibitor of PI3Kδ, with a pIC50 of 10.1. GSK2292767 showing greater than 500-fold selective over the other PI3K isoforms. GSK2292767 can be used for the research of respiratory disease[1]. |
| Name | N-{5-[4-(5-{[(2R,6S)-2,6-Dimethyl-4-morpholinyl]methyl}-1,3-oxazo l-2-yl)-1H-indazol-6-yl]-2-methoxy-3-pyridinyl}methanesulfonamide |
|---|---|
| Synonym | More Synonyms |
| Description | GSK2292767 is a potent and selective inhibitor of PI3Kδ, with a pIC50 of 10.1. GSK2292767 showing greater than 500-fold selective over the other PI3K isoforms. GSK2292767 can be used for the research of respiratory disease[1]. |
|---|---|
| Related Catalog | |
| Target |
PI3Kδ:10.1 (pIC50) |
| In Vitro | GSK2292767 exhibits high clearance (50 mL/min/kg) in vivo and low oral bioavailability (F < 2%) in a rat PK study[1]. GSK2292767 (0.01-1 μM) has no effect on QT interval, Tp‑e, or QRS and no significant risk of TdP arrhythmias in a rabbit cardiac ventricular wedge assay[1]. GSK2292767 protect against eosinophil recruitment with an ED50 of 35 μg/kg in the brown Norway rat acute OVA model of Th2 driven inflammation in the lungs of rats[1]. |
| References |
| Molecular Formula | C24H28N6O5S |
|---|---|
| Molecular Weight | 512.58100 |
| Exact Mass | 512.18400 |
| PSA | 143.85000 |
| LogP | 4.36090 |
| Storage condition | -20℃ |
| N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide |
| AZD 4547 |
| QCR-89 |
| N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]benzamide |
| GSK2292767 |